Skip to main content
RAMM Pharma Corp. logo

RAMM Pharma Corp. — Investor Relations & Filings

Ticker · RAMM CSE Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2026-04-02 Regulatory Filings
Country CA Canada
Listing CSE RAMM

About RAMM Pharma Corp.

https://www.wearerammpharma.com/

RAMM Pharma Corp. is a pharmaceutical and medical product company specializing in cannabinoid pharmacology and product formulation. The company develops and commercializes plant-derived cannabinoid pharmaceuticals, cosmetics, and pet care products. Key operations include Medic Plast, which produces medically registered prescription CBD solutions (Epifractán and Xalex 10) approved by the Ministry of Public Health of Uruguay. RAMM also addresses the pet market through NettaLife (NettaVet CBD drops and NettaPet food) and the European cosmetic and nutraceutical sectors via Canapar, which operates a high-tech cannabis extraction facility in Sicily. The company utilizes cultivation facilities in Uruguay and focuses on expanding distribution agreements across Latin America.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate” under Canadian NI 52-109 certifying the interim financial report and interim MD&A. It is not the interim report itself but a required regulatory certificate filing under securities legislation. It does not announce an upcoming report (RPA) nor fit into any more specific category; it is a miscellaneous regulatory filing. Therefore, it should be classified as Regulatory Filings (RNS).
2026-04-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 80% confidence The document is a standalone Form 52-109FV2 certification for interim filings (CFO certificate), not the actual interim financial report or MD&A, nor an announcement of a report release. It does not fit categories like IR (which covers the full interim report), RPA (which covers announcements of report availability), or any other specific filing type (e.g., audit, earnings release). Therefore it defaults to a general regulatory filing.
2026-04-02 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled “Management's Discussion & Analysis for the three months ended January 31, 2026” and contains management’s detailed narrative on strategy, operations, financial results, outlook, and risks for the interim period. It is an MD&A rather than the full interim financial statements or a simple announcement. This aligns precisely with our “Management Reports” category (MDA).
2026-04-02 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for RAMM Pharma Corp. for the three months ended January 31, 2026. It includes comprehensive financial statements (Statement of Financial Position, Statement of Loss, Statement of Changes in Equity, Statement of Cash Flows) and detailed notes to the financial statements. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2026
2026-04-02 English
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a supplemental disclosure provided by RAMM Pharma Corp. in connection with an upcoming Special Meeting of Shareholders. It details a proposed 'related party transaction', explains the rationale, discusses the involvement of a special committee, and provides information on the counterparty (Global South). Because this document is specifically designed to provide additional information to shareholders to inform their vote at an upcoming meeting, it falls under the category of Proxy Solicitation & Information Statement materials.
2025-11-07 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 80% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate certifying the interim financial report and interim MD&A for the period ended July 31, 2025. It is a CEO’s certification letter under Canadian NI 52-109, not the interim report or its MD&A itself, nor an announcement of publication, earnings release, or other financial supplement. There is no category for a standalone certification of interim filings, so it defaults to a general regulatory filing.
2025-09-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.